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Abstract  
Objectives. Anti-tumour necrosis factor antibody (anti -TNF) has revolutionised the treatment of rheumatoid 
arthritis (RA) and remission is now a realistic possibility for patients. Despite widespread use of anti-TNFs, 
predicting which patients are most l ikely to attain a sustained good response to these treatments remains 
challenging. Our objective was to undertake a systematic review of the literature to evaluate existing evidence 
for demographic and clinical factors associated with the achievement of sustained remission in individuals with 
RA treated with anti -TNF. 
 
Methods. EMBASE, MEDLINE and the Cochrane Controlled Trials Register were searched along with studies 
identified from reference lists . Quality of studies was assessed using Newcastle-Ottawa criteria. Meta-analysis 
was undertaken where unadjusted odds ratios  were available for the same demographic or clinical factors from 
at least three studies. 
 
Results. Six studies were identified. Concomitant methotrexate use was associated with an increased likelihood 
of achieving sustained remission. Greater baseline disease activity, tender joint count, age, disease duration, 
baseline functional impairment and female gender were associated with reduced likelihood of achieving 
sustained remission.  
 
Conclusions. Factors predicting sustained remission are seldom reported. Evidence identified in this review 
supports current recommendations for methotrexate co-prescription and highlights the negative impact of 
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particular clinical and demographic features on the likelihood of achieving optimal response to anti -TNF 
treatment. Sustained remission is clinically more relevant than point remission in RA. More widespread 
reporting of sustained remission will  help clinicians set realistic expectations on likely long-term treatment 
efficacy and could be an important tool for identifying patients suitable for dose optimisation.  
 
 
 
 
Significance and Innovation 
 Demographic and clinical features can help to predict s ustained remission with anti-TNF.  
 Female gender is associated with a reduced likelihood of achieving sustained remission. 
 Methotrexate co-prescription with anti -TNF is associated with an increased likelihood of achieving 
sustained remission. 
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Aggressive treat-to-target strategies, alongside increased use of biologic agents such as anti -tumour necrosis 
factor antibody (anti -TNF)(1,2), have improved outcomes for patients with rheumatoid arthritis (RA) and the 
aim of achieving sustained remission is a realistic aspiration.  
 
Response to anti -TNF, however, remains variable and requires further investigation. Waiting to assess efficacy 
of anti-TNF is time-consuming, often taking months for clinicians and patients to identify that the treatment is 
not working, and can be frustrating if anticipated clinical improvements do not materialise. Unsuccessful trials 
of anti-TNF therapy in RA also have important healthcare cost implications.  Understanding how the 
demographic and clinical features of a patient may influence the likelihood of achieving sustained remission with 
anti-TNF will  help physicians personalise treatment strategies and might enable patients to achieve sustained 
remission sooner through early choice of drug that offers the best l ikelihood of success. 
 
The majority of published studies report remission rates at a single time point, or sequential point remission 
rates. It may be unclear whether the proportion of patients identified in remission at sequential time points are 
the same patients, or are a varying group of individuals, with some patients moving in and out of remission over 
time. European League Against Rheumatism (EULAR) guidance (3) recommends achieving remission as early as 
possible with consideration of tapering anti -TNF agents if sustained remission is achieved, and Outcome 
Measures in Rheumatology (OMERACT) define the duration of sustained remission as six months (4). Previous 
systematic reviews have only investigated predictors of point remission in RA (5), however, given the chronicity 
of a condition such as RA and the long-term benefits of remission, a durable positive response to anti -TNF is a 
more clinically relevant outcome. 
 
Our objective was to undertake a systematic review of the literature to evaluate the existing evidence for 
demographic and clinical factors associated with the achievement of sustained remission in individuals with RA 
treated with anti -TNF. 
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Patients and Methods 
The systematic review protocol was registered prospectively with the PROSPERO database  
(http://www.crd.york.ac.uk/PROSPERO/, reference CRD42015015983). PRISMA-P (6) and PRISMA (7) 
recommendations were followed in the development and implementation of the review. 
Inclusion criteria 
To be included in the review, papers had to meet the following criteria:  
1) Phase three or four clinical trials, long-term extension trials or cohort studies reported as original research in 
the form of journal papers;  
2) Adults (≥18 years of age) with RA according to ACR 1987(8) or ACR/EULAR 2010 (9) criteria; 
3) Report on anti-TNF used for the treatment of RA; 
4) Report on at least one measure of RA disease activity using DAS (10), DAS28 (11,12), CDAI(13), SDAI (14), 
ACR/EULAR remission (15) or ARA 1981 remission criteria (16); 
5) Report on predictors of sustained remission (at least six months)(4).   
Exclusion criteria 
Studies where it was not possible to isolate the required data on patients in sustained remission, case-control, 
cross-sectional studies, case reports/series, phase one and two/laboratory studies, qualitative studies, survey-
based studies, narrative reviews, conference abstracts and editorials were excluded. 
 
Search methods for identification of studies   
EMBASE, Medline and the Cochrane Controlled Trials Register were searched using the Ovid platform to 4 th 
September 2015. The full  search strategy for Medline is provided in supplementary online table 1. No language 
restriction was applied to search results. Reference lists of included studies were searched for additional  
citations and all authors were contacted for additional information to assist with the review and meta -analysis. 
Additional data were kindly provided by Dr Barnabe, Dr Einarsson, Dr Balogh, and Professor Tanaka.  
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Assessment of studies for inclusion in the review 
All search results were dual screened with dual data extraction and quality scoring using a custom Access™ 
database. The quality of studies was assessed using the Newcastle-Ottawa Scale(17).  A narrative review of 
studies with relevant quantitative data extraction was undertaken. Corresponding authors were contacted to 
obtain unadjusted data to enable meta-analysis where appropriate. Sources of heterogeneity were investigated 
through structured critical appraisal.   
Meta-Analysis 
Statistical analysis was undertaken using Review Manager Software version 5.3(18). Because the factors 
incorporated in calculating adjusted odds ratios (OR) were not consistent between studies, unadjusted OR were 
used in meta-analysis where data were available from at least three studies . A random effects model was used 
to allow for between study variation. Heterogeneity between studies was assessed using I2 (19) and publication 
bias was assessed using funnel plots. 
Results 
Study identification 
4438 papers were identified from the search strategy. 4220 records were excluded and 218 full  text papers, 
including 50 randomised controlled trials, were assessed. Six papers met the inclusion criteria and were included 
in the review (20-25). One of these papers (24) had included one patient aged less than 18 years old in one 
subgroup (personal correspondence), however, the mean age of all  the subgroups and the overall  cohort was in 
l ine with the other included papers, and it was decided to include the study in the review. The screening process 
is summarised in Figure 1.  
 
Study design 
The characteristics of the included studies (and quality assessed using Newcastle-Ottawa scores) are 
summarised in Tables 1 and 2.  Two of the included studies were multicentre studies (23,24), coordinated from 
one hospital, one of which was an open label, non-randomised trial(23). One study was a retrospective case 
note review (26) and three were registry studies (20,21,25). 
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Sources of Heterogeneity 
All studies included in this review were observational by design and therefore there was variation in the range 
of treatments and patients included. Neither of the two multicentre studies (23,24), or the retrospective case 
note review (26) described their selection criteria and therefore there is a potential for the introduction of bias. 
Three of the included papers were registry studies (20,21,25) and are more likely to be representative of the 
general RA population treated with anti -TNF.  
 
Definitions of sustained remission utilised 
The definitions of sustained remission varied across the included studies. The minimum length of time that 
different studies defined sustained remission, varied from at least six months, to nine months, or ‘two 
consecutive visits’ (verified to be at least six months (27)); and a range of outcome measures (DAS28, CDAI, SDAI, 
ACR/EULAR criteria) were also used. Additionally, Einarsson et. al. (25) did not exclude patients who were in a 
state of sustained remission who had a single episode of increased disease activity. However, it was less clear 
how the other studies handled these cases.  
 
Missing data 
The extent of missing patient data in sustained remission was not clear in the study by Balogh et al. (24); and 
detail  on 25% (seven patients) of the cohort in sustained remission was missing from the study by Brocq et al. 
(22) which meant that data from these studies could not be included in meta -analysis. A total of 46 patients 
(1.9%) were lost to follow-up in the study undertaken by Einarsson et. al. (25), and last observation carried 
forward and LUNDEX correction was used to account for incomplete follow-up visits (28). Barnabe et al(20) and 
Furst et.  al. (21) did not use imputation, but did not give any information on missing data. Last observation 
carried forward was used to impute missing data in the HONOR Study (23). 
 
Achievement of sustained remission 
There was wide variation in rates of sustained remission. The highest rate of DAS28 sustained remission was in 
the HONOR study (23) (38.1%), and the lowest rate of DAS28 sustained remission was noted in the CORRONA 
population (21) (7.9%).  
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Anti-TNFs and concomitant medications studied 
The studies identified in this systematic review include a range of anti -TNF medications. Some studies 
(20,22,23,25) specifically reported which anti -TNFs were studied, whereas the studies by Furst et al.(21) and 
Balogh et al. (24) did not. Very l ittle data was available for patients using the newer anti -TNF medications 
(certolizumab pegol and golimumab), and no data were available for biosi milar anti-TNF medications. 
Additionally, the use of concomitant allowable drug use (such as prednisolone and NSAIDs) differed between 
included studies (Table 2). 
 
Despite these differences, there were many similarities in the baseline demographics, includ ing mean age, 
gender, and concomitant synthetic disease modifying anti rheumatic drug (DMARD) use (Table 2) suggesting 
that although there is l ikely to be heterogeneity between studies, there are sufficient similarities to allow 
comparison between studies. 
 
Impact of patient demographics on sustained remission  
  
Gender. Female gender was negatively associated with DAS28 sustained remission in two of the studies (21,25) 
(Table 3). In contrast, Barnabe et al. did not find female gender to be significantly associated with sustained 
remission by DAS28, ACR/EULAR 2011, or SDAI criteria using multivariate modelling, although univariate analysis 
(personal communication; univariate analysis used in meta -analysis) did suggest an association. No association 
between sustained remission and gender was identified by Tanaka et al. (23), and was not reported by the 
remaining studies (22,24). Meta-analysis demonstrated a reduced likelihood of achieving sustained remission 
in females compared with males with low data heterogeneity and a low likelihood of publication bias ( Figure 
2). 
 
Age. Increasing age was negatively associated with sustained remission by DAS28 in three of the studies 
(21,24,25) but was not associated with sustained remission in the study by Tanaka et al .(23) and was not 
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reported by the remaining studies (20,22). Uniform unadjusted data were not available for this variable to 
enable meta-analysis.  
 
Obesity. The only study to report the relationship between obesity and sustained remission identified a negative 
association according to ACR/EULAR Boolean criteria excluding the CRP, but not by the other remission criteria 
included in the study (20).  
Impact of disease characteristics on sustained remission 
 
Baseline disease activity. Higher baseline disease activity was associated with a reduced likelihood of achieving 
sustained remission using the DAS28 score (21,23,25) and CDAI (21). No association was noted between 
baseline disease activity and subsequent sustained remission in the multivariate analysis by Barnabe et al .(20).  
The association between baseline disease activity and attainment of sustained remission was not reported in 
the remaining studies (22,24).  
 
Patient Global Score. A lower baseline patient global score was associated with sustained remission in the 
HONOR study (23). However, the only other study to include patient global scores did not identify any 
association (20).  
 
Acute phase reactants. An elevated erythrocyte sedimentation rate (ESR) was negatively associated wi th 
sustained remission in the HONOR study (23), but not in the study by Barnabe et al.(20). The C-reactive protein 
(CRP) did not predict sustained remission in the two studies where it was reported (20,25). 
 
Number of tender and swollen joints. A greater number of tender joints negatively predicted sustained remission 
by CDAI criteria (20) and DAS28 criteria (24). However, no association was identified by Tanaka et al.(23). A 
higher swollen joint count was not identified as being associated with sustained remission in any of the four 
studies that reported this data (20,21,23,24). 
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Functional impairment. Higher rates of patient-reported functional impairment at baseline (assessed using the 
Stanford Health Assessment Questionnaire; HAQ) were consistently associated with lower rates of sustained 
remission (21,23,25). Only one study did not identify an association between baseline HAQ score and sustained 
remission on multivariate analysis (20). The effect of baseline functional impairment on remission s tatus was 
not reported in the remaining studies (24,26). 
 
Disease duration. One study identified that increased disease duration (stratified into five-yearly increments) 
was associated with a decreased likelihood of achieving sustained remission with the CDAI but not DAS28 criteria 
(21). Shorter disease duration was associated with an increased likelihood of achieving sustained DAS28 
remission in one study (23). The remaining studies either found no association (20,25) or did not report on the 
association between disease duration and sustained remission (22,24).  
 
Early response to treatment. Response at 16 weeks after treatment was only reported by one study (20) and 
was associated with an increased likelihood of achieving of sustained remission by DAS28 cri teria. 
 
Concurrent and Past Medication Use  
 
Methotrexate. Concomitant methotrexate use was positively associated with sustained remission by DAS28 
criteria (21,25) and CDAI (21). However,  Tanaka et al. (23) did not find any significant difference in baseline 
methotrexate dose between the sustained and non-sustained remission groups.  
 
Prednisolone. Prednisolone use was negatively associated with sustained CDAI but not sustained DAS28 
remission in one study (21). However, no association was identified in the study by Einarsson et. al.(25). 
Prednisolone use was restricted to a stable dose of less than 5mg in one study (26) and patients taking 
concomitant corticosteroids were excluded from two studies (20,23). The remaining study did not report 
corticosteroid use(24). 
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Prior anti-TNF use and Efficacy. Furst et al .(21) was the only study to report data on prior anti -TNF use and found 
that this was negatively associated with sustained remission in both DAS28 and CDAI measurements. Einarsson 
et al.(25) investigated time to sustained remission for each anti -TNF and found that etanercept was associated 
with an increased likelihood of achieving sustained remission within the first twelve months on treatment when 
compared with infl iximab. 
Discussion 
Despite the variability in both the definition of sustained remission, and the predictive factors reported by each 
study, some common themes have emerged.  One of the most striking findings was the paucity of evidence 
available for factors associated with sustained remission as an outcome. From over 4000 possible manuscripts 
identified in the search, only six studies were identified which met the inclusion criteria, all of which were 
observational. With the exception of one study (23), only 4.5% - 15.8% of patients were identified as being in 
sustained remission in any of the studies.  
      
A number of clinical factors including increased disease duration, higher baseline disease activity score, 
increased baseline tender joint count, and a greater baseline functional impairment are associated with a 
reduced likelihood of achieving sustained remission. Demographic factors that appear to be negatively 
associated with sustained remission include female gender and increasing age. Only one clinical factor 
(methotrexate co-prescription) was associated with an increased likelihood of achieving sustained remission in 
more than one study. Supporting these findings, Katchamart et al. also identified these factors as predictors of 
point remission in a systematic review (5). Interestingly, the rates of sustained DAS28 remission identified in this 
review (7.9 – 38.1%) compare favourably with the range of point DAS28 remission rates (5 - 40%) identified by 
Katchamart et. al. However, the studies identified by Katchamart et.al. included both biologic and synthetic 
DMARD treated RA patients enrolled in studies between 1999 to 2008. By comparison, this review focused on 
anti-TNF treated patients only, and the oldest study in this review dates from 2009. 
 
Our review identified that female gender appears to be strongly associated with a reduced likelihood of 
achieving sustained remission in two of the included studies. However, female gender has been associated with 
a higher baseline ESR in a normal ‘healthy’ population compared with males, and is also known to increase with 
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age (29). Given ESR is a component in the DAS28-ESR, it is possible that variations in gender and age may be 
confounders in the interpretation of the score which does not have different thresholds for these factors, rather 
than being true predictors of poor response. This may explain why Furst et al.(21) identified that female gender 
was associated with a lower l ikelihood of achieving sustained remission when using DAS28 -ESR criteria, but not 
when using CDAI (which does not include an inflammatory marker component). 
 
The finding that both increasing age and longer disease duration are both associated with a reduced likelihood 
of achieving sustained remission is unsurprising, and further studies are required to ascertain the independence 
of these effects. An important finding is the impact of baseline functional impairment on likelihood of achieving 
sustained remission. However, it remains uncertain whether worse functional impairment is a true predictor of 
response, or acting as a proxy marker of recalcitrant higher disease activity, irreversible joint damage, pain or 
fatigue, which may not be responsive to anti -TNF. 
 
The only intervention that was associated with an increased likelihood of achieving sustained remission was 
methotrexate co-prescription. Whilst there may be alternative causal pathways  that are responsible for this 
association (e.g. confounding by indication arising from the differing tolerance of methotrexate between 
patients), and it is difficult to assess cause and effect pathways using solely observational data, this association 
does appear to support the practice of co-prescription of methotrexate with anti -TNF wherever possible(30).  
 
There was an absence of any comorbidity data in the included studies. Furst et. al.(21) and Einarsson et al (25) 
both describe collection of comorbidity data, however no analysis was reported. None of the other studies 
included any reporting on comorbidity data. The association between RA and increased cardiovascular risk is 
well documented (31), as is the apparent risk reduction in RA patients successfully treated with anti -TNF (32). 
However, this review did not identify any evidence on cardiovascular outcomes in RA patients achieving 
sustained remission with anti -TNF. 
 
Interaction between predictors and outcomes is challenging when using composite score outcome measures , 
particularly when variables included in the score are also identified as a predictor of that score. All  the disease 
activity outcome measures used in RA are composite measures, and some of the predictors identi fied in this 
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review, and the review by Katchamart et al. (5), are also components of these scores. An example of this is the 
association between higher baseline tender joint count and reduced likelihood of achieving su stained remission. 
It is unknown if having more tender joints prior to starting anti -TNF is a negative predictor of achieving sustained 
remission, or whether there is interaction with the composite outcome measure, within which tender joint count 
comprises a component. This review also identified that higher baseline disease activity was negatively 
associated with the likelihood of achieving sustained remission; although this association may be on the causal 
pathway in the relationship between tender joint count and sustained remission. It is possible that composite 
disease activity scores may not be efficient at measuring reduction in inflammatory burden. Due to the 
multifaceted nature of a composite outcome measure, non-inflammatory components (such as the global health 
measure) may reduce the sensitivity in detecting the change in inflammatory activity achieved by anti -TNFs.  
 
A surprising finding was that no objective clinical measure (such as the swollen joint count or inflammatory 
marker) was associated with sustained remission. It may be that improvements in objective measures of disease 
activity improve more uniformly in response to anti -TNF in the majority of patients, whereas the more subjective 
components of the disease activity score and patient di rected outcome measures (such as the HAQ) are more 
variable in their response to anti -TNF. The world health organisation international classification of functioning, 
disability and health (WHO-ICF)(33) recognises the multi -faceted nature of an individual’s perception of health, 
disability and functioning, and may provide some insight as to why there appears to be no association between 
sustained remission and objective measures of disease activity. In the WHO -ICF model, the actual health 
condition only accounts for one of six dimensions that contribute to an individual’s perception of health and 
functioning. Participation in l ife situations, l imitations on ability to undertake activities, impairment to body 
functions, environmental aids or barriers and personal factors all interact in an individual’s perception of health. 
Quantification and reporting quality of l ife (such as fatigue) is a problem encountered in many chronic conditions  
and a recent Cochrane review demonstrated modest improvement in fatigue in response to anti -TNF and other 
biologic therapy (34). However, a cross-sectional evaluation of the British Society for Rheumatology Biologics 
Registry for RA (BSRBR-RA) investigating fatigue remission identified that only 37% of those individuals who 
achieved DAS28 remission at 6 months achieved a corresponding remission of their fatigue (35).  
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All the composite outcome measures included in this review contain components that indirectly measure non-
disease dimensions (the global health measure). Personal factors also contribute to a patient’s reporting of these 
subjective components. Therefore, the reduction in inflammatory burden could be offset by a lack of effect on 
subjective components of the score, which may not be directly related to disease activity. This poses wider 
questions for the use of composite outcome measures to quantify therapeutic efficacy of a targeted drug such 
as anti-TNF. Whilst blockade of the TNF pathway reduces joint damage, inflammation and swelling of active RA, 
it may be that a patient’s pain and fatigue is dr iven by other factors unrelated to their RA. In these cases, 
classifying the patient as a ‘non-responder’ to anti -TNF is inappropriate. However, none of the studies identified 
in this review presented data on possible confounders such as  fatigue, so we are unable to comment on the 
relationship between such factors and sustained remission.  A future approach for identifying the impact of non-
inflammatory factors in the composite outcome measure may be to measure key quality of l ife metrics (such as 
fatigue, mood etc.) at two six monthly intervals prior to addition of anti -TNF therapy, with subsequent regular 
measurement thereafter. If reductions  in objective markers of inflammation are noted, but subjective markers 
and quality of l ife measures remain poor, therapies targeted at addressing quality of l ife factors  may be more 
efficacious in eliciting a favourable outcome than switching RA treatment modality.  
Conclusions 
Despite the clinical relevance sustained remission remains a poorly reported outcome. Reporting the number of 
patients in a sustained state of remission or low disease activity, and their clinical features, would not require 
any additional data collection than currently occurs in most clinical studies, and would greatly assist in assessing 
the real-world clinical benefit of these treatments to patients. Furthermore, understanding of how individual 
components of composite outcome measures (such as the DAS28) vary in response to disease modifying 
treatment is needed in order to appropriately tailor treatment to the individual. 
 
With the increasingly widespread use of anti -TNF therapy, and aspirations of moving towards personalised 
medicine, understanding which patients achieve the most profound and durable therapeutic effect is essential 
to ensuring high quality and cost-effective management decisions, as well as considering the wider context in 
which an individual’s disease sits.  
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Table 1. Newcastle-Ottawa Quality Scoring 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Score Acceptable 
Brocq 
2009 
Furst 
2011 
Balogh 
2013 
Barnabe 
2014 
Einarsson 
2015 
Tanaka 
2015 
Se
le
ct
io
n
 
Representativeness of the 
exposed cohort 
Truly or somewhat representative of the average 
RA patient using anti-TNF in the community 
Nil * Nil * * Nil 
Representativeness of the non-
exposed cohort 
Drawn from the same community as the exposed 
cohort 
* * * * * * 
Ascertainment of exposure Secure record or structured interview * * * * * * 
Demonstration that the 
outcome was not present at the 
start of the study 
Documented that patients were not in remission 
at the time of entry 
* * * Nil Nil * 
C
o
m
p
ar
ab
il
it
y 
Comparability of cohorts Subgroups (exposed and non-exposed) were 
drawn from the same cohort (2 stars) 
** ** ** ** ** ** 
O
u
tc
o
m
e
 
Assessment of outcome Independent blind assessment or record linkage * * * * * * 
Was follow-up long enough for 
outcome to occur 
At least 6 months follow-up after the first review 
following baseline visit  
* * * * * * 
Adequacy of follow-up All subjects accounted for or <10% of patients lost 
to follow-up (unless detailed description that 
those lost to follow-up would not have 
introduced bias) 
Nil Nil * * * * 
Summary Selection (Max 4 *) *** **** *** *** *** *** 
Comparability (Max 2*) ** ** ** ** ** ** 
Outcome (Max 3*) ** ** *** *** *** *** 
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Table 2. Summary of Studies & Baseline Characteristics  
 
 
 
                                                 
1 Data extracted from referenced paper Brocq 2007(36). 
Author, year Country Study 
Duration & 
Design 
Sample Size 
& Gender 
(Female) 
Anti-TNF group 
inclusion criteria 
Co-medication 
(included/ 
excluded) 
Mean 
Age & 
disease 
duration 
(yrs) 
 
Disease 
activity 
measure 
Mean +/- SD 
disease activity 
HAQ score, mean or 
median +/- SD or (range) 
Proportion of Cohort in Sustained 
Remission (%), Criteria 
Brocq 2009 France 7 years,  
Retrospective 
Cohort 
304, 81.3%1  RA patients with 
failure of 
methotrexate and 
DAS28 ≥ 5.1. 
Previous anti-TNF 
treatment allowed. 
Included 
Prednisolone 
(≤5mg) 
Synthetic DMARD 
(stable dose) 
 
Excluded  
NSAID users 
581, 10 1 DAS28 6.41  Not given 8.2% DAS28 
Furst 2011 USA 7 years, 
Prospective 
Cohort 
(stratified by 
disease 
duration) 
3170, 77.4-
79.8% 
(depending 
on subgroup) 
 
RA patients starting 
on anti-TNF 
Included 
Synthetic DMARD 
(dose unspecified) 
 
Excluded 
None specified 
54.3, 2.5 DAS28 4.4 ± 1.4 
M
-H
A
Q
 v
al
u
e
s 
0.5 (mean) ± 0.5 (SD) 8.9%, DAS28 Overall cohort 
sustained 
remission 
7.6% by CDAI 
and 7.9% by 
DAS28 
CDAI 21.8 ± 13.7 9.7%, CDAI 
54.1, 7.7 DAS28 4.5 ± 1.5 0.5 (mean) ± 0.5 (SD) 11.6%, DAS28 
CDAI 21.0 ± 13.8 9.5%, CDAI 
60.5, 20.3 DAS28 4.6 ± 1.5 0.6 (mean) ± 0.5 (SD) 4.9%, DAS28 
CDAI 21.5 ± 13.1 4.2%, CDAI 
Balogh 2013 Ireland 1 year, 
Prospective 
Cohort  
273, 74.4% Biologic naïve RA 
patients with 
persistent disease 
activity starting on 
anti-TNF 
None specified 59.9, 13.4 DAS28, 
ACR/EULAR 
5.33 ± 1.07 Not given 9.9%, DAS28 (from ACR/EULAR 
subgroup) 
Barnabe 2014 Canada 7 years, 
Prospective 
Cohort 
1116, 74.0% Biologic naïve, RA 
refractory to 
parenteral 
methotrexate/ 
leflunomide, at 
least 2 study visits 
None specified 54.4, 12.2 DAS28 6.03 ± 1.30 1.62 (mean), 0.68 21.5%, DAS28  
CDAI 38.52 ± 13.59 9.9%, CDAI 
SDAI 40.90 ± 14.66 4.5%, SDAI 
ACR/EULAR 
2011 (no 
CRP) 
NA 10.8%, ACR/EULAR 2011 (minus CRP 
component)  
ACR/EULAR  NA 6.8%, ACR/EULAR 2011  
Tanaka 2015 Japan 3 years, Open 
label, non-
randomised 
study 
197, 84.8% RA patients with 
inadequate 
response (DAS28-
ESR ≥3.2) to 
Methotrexate 
and/or other non-
biological DMARDs 
Included 
None specified 
 
Excluded 
Steroid use 
NSAID and Coxib 
use 
Variable synthetic 
DMARD use 
60.7, 8.9 DAS28-ESR 5.4  Not given 38.1%, DAS28-ESR  
Einarsson 2015 Sweden 10 years, 
Prospective 
cohort 
2416, 77% RA patients with 
active disease + ≥1 
failed previous 
DMARD. Previous 
biologic allowed. 
None specified 56.0, 11.8 DAS28 5.5  1.3 (mean) 15.8%, DAS28 
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Table 3. Predictors of sustained remission  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study (n) Predictor Outcome Measure Used Effect Size Association with 
Sustained Remission 
B
ar
n
ab
e
 2
0
1
4
 
(1
1
1
6
) 
Baseline Physician Global (High) DAS28 OR 0.80, 95% CI 0.66–0.99 Negative 
Obesity ACR/EULAR Boolean  
(excluding CRP) 
OR 0.30, 95% CI 0.10–0.90  
Tender Joint Count (High) CDAI OR 0.96, 95% CI 0.92–1.00  
Early response to treatment (<16 weeks) DAS28 OR 1.88, 95% CI 1.27 – 2.78 Positive 
Fu
rs
t 
2
0
1
1
 
(3
1
7
9
) 
Higher baseline disease activity  DAS28 OR 0.37, 95% CI 0.19 – 0.73  Negative 
CDAI OR 0.57, 95% CI 0.39 – 0.84 
Disability CDAI OR 0.25, 95% CI 0.08 – 0.79 
Increased disease duration (5-yearly increments)  CDAI (but not by DAS28) OR 0.85, 95% CI 0.75 – 0.97 
Age  DAS28 (but not by CDAI) OR 0.79, 95% CI 0.63 – 1.00 
Female gender DAS28 (but not by CDAI) OR 0.43, 95% CI 0.23 – 0.82 
Concomitant prednisolone  CDAI (but not by DAS28) OR 0.69, 95% CI 0.47 – 1.00 
Prior anti-TNF use CDAI OR 0.98, 95% CI, 0.96 – 1.00 
DAS28 OR 0.72, 95% CI, 0.54 – 0.94 
Concomitant methotrexate CDAI OR 1.55, 95% CI 1.00 – 2.42 Positive 
DAS28 OR 2.83, 95% CI 1.18 – 6.80  
B
al
o
gh
, 
2
0
1
3
 
(2
7
3
) 
Tender Joint Count DAS28 (as a subgroup of ACR/EULAR 
criteria) 
 
OR 0.910, p 0.031 Negative 
Increasing Age OR 0.942, p<0.0001 
Ta
n
ak
a 
2
0
1
5
 
(1
9
7
) 
Lower Patient Global Score DAS28-ESR 
 
41.3 vs. 54.9 mm, p=0.0004 Positive 
 Shorter disease duration 7.5 vs. 9.6 yrs, p= 0.005 
Lower baseline HAQ-DI score  0.96 vs. 1.42, p<0.0001 
Lower baseline ESR 44.1mm/hr vs. 53.0 mm/hr, p=0.0374 
Lower baseline DAS28-ESR 5.11 vs. 5.70, p=0.005 
Ei
n
ar
ss
o
n
 2
0
1
5
 
(2
4
1
6
) 
Female Gender DAS28 OR 0.57, 95% CI 0.44 – 0.75 Negative 
Higher baseline disease activity OR 0.62, 95% CI 0.55 – 0.70 
Earlier calendar year of starting anti-TNF  OR 0.89, 95% CI 0.85 – 0.93 
Higher HAQ OR 0.39, 95% CI 0.31 – 0.49 
Increasing age  OR 0.98, 95% CI 0.97 – 0.99 
Concomitant Methotrexate  OR 2.02, 95% CI 1.51 – 2.71 Positive 
Remission RA & Anti-TNF: Systematic Review 
 
 
 
Supplementary Online Table 1. Medline Search Criteria  
Diagnosis (KW.)  Drug (OR, KW.)  Outcome (OR, KW.) 
Rheumatoid arthritis 
(74933) 
 
 
 
 
A
N
D 
Tumor necrosis factors* (2066) 
Tumor Necrosis factor-alpha* (116033) 
Antibodies, Monoclonal* (180019) 
Antibodies, Monoclonal, Humanized* (25271) 
Antibodies, Monoclonal, Murine-Derived* (9706) 
Receptors, Tumor Necrosis Factor* (16571) 
 
Certolizumab pegol. kw  (373)  
Golimumab. kw  (326)  
Infliximab. kw  (8655)  
CT-P13* (Infliximab biosimilar). kw  (3) 
Adalimumab. kw  (3549)  
Etanercept. kw  (4027) 
 
Anti-TNF .kw  (6196) 
Tnf.kw  (108867) 
TNFR-Fc fusion protein .kw  (4201) 
 
Combined hits w ith OR 328541 
 
Diagnosis AND Drug combined give 10829 hits 
 
 
 
 
 
 
A
N
D 
Remission, Spontaneous* (15099) 
Treatment outcome* (658026) 
Severity of illness Index* (171810) 
Reproducibility of Results* (281754) 
Remission Induction* (32979) 
Induction Chemotherapy* (5743) 
Recovery of Function* (34252) 
Pharmacology, clinical* (2201) 
Drug evaluation* (80081) 
Drug utilization* (20410) 
Evaluation Studies as Topic* (119716) 
Maintenance Chemotherapy* (1435) 
Quality of Health Care* (115945) 
Sustained remission (kw ) (930) 
Maintained remission (kw ) (130) 
Prolonged remission (kw ) (611) 
Responder (kw ) (10266) 
Disease control (kw ) (46264) 
Disease activity (kw ) (24636) 
DAS28 (kw ) (1474) 
Clinical Disease Activity Index (kw ) (184) 
Simplif ied Disease Activity Index (kw ) (128) 
DAS (kw ) (42944) 
Remission (kw ) (109223) 
 
Combined above hits w ith OR 1676984 
 
 
*Denotes MeSH heading 
(kw) denotes keyword 
 
Search Performed using Ovid interface on 4 th September 2015 
All above articles were searched as keywords- Diagnosis AND Drug AND Outcome gives 3797 hits  
Limit to humans, and adolescent, all adult, young adult, middle age, middle aged, all aged, aged- gives 2413 hits
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Figure 1. Results of Citation Screening 
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 Figure 2. (a) Effect of gender on likelihood of achieving sustained remission and (b) publication bias 
 
 
 
 
 
 
 
 
 
 
 
